Genetic Testing Market Research Report - Forecast till 2027

遺伝子検査市場:タイプ別情報(処方遺伝子検査および消費者向け遺伝子検査)、方法(分子遺伝子検査/ DNA検査、染色体遺伝子検査、生化学的遺伝子検査)、アプリケーション別(リプロダクティブヘルス(新生児スクリーニング、出生前スクリーニング、キャリアスクリーニング)、がん検診(遺伝性がん、乳がん、卵巣がん、結腸がん)、祖先、予測および症状前検査など)-2027年までの予測

ID: MRFR/HC/1477-CR | February 2021 | Region: Global | 150 Pages         

1 Introduction

1.1 Definition 15

1.2 Scope of the Study 15

1.3 List of Assumptions 16

1.4 Market Structure 16

2 Research Methodology

2.1 Research Process 17

2.2 Primary Research 18

2.3 Secondary Research 19

2.4 Market Size Estimation 20

2.5 Forecast Model 20

3 Market Dynamics

3.1 Introduction 21

3.2 Drivers 22

3.2.1 Rising Awareness About the Benefits of Genetic Testing 22

3.2.2 Rising Prevalence of Genetic Disorders 22

3.2.3 Genetic Tests Play an Important Role in Forensic Investigations 22

3.2.4 Changing Trend in the Industry from Service-Driven to Product-Driven Industry 22

3.3 Restraints 23

3.3.1 Limitations in Genetic Testing and Inaccuracy of Tests 23

3.3.2 High Cost of Tests 23

3.4 Opportunities 23

3.4.1 Growth in Untapped Regions and Developing Economies 23

3.5 Challenges 23

3.5.1 Growth in Exposure to Natural and Man-Made Threats 23

3.6 Macroeconomics 24

3.7 Technology Trends & Assessment 24

4 Market Factor Analysis

4.1 Value Chain Analysis 25

4.1.1 R&D and Designing 25

4.1.2 Manufacturing 25

4.1.3 Distribution & Sales 26

4.1.4 Post-Sales Review 26

4.2 Porter’s Five Forces Model 27

4.2.1 Bargaining Power of Suppliers 28

4.2.2 Bargaining Power of Buyers 28

4.2.3 Threat of New Entrants 28

4.2.4 Threat of Substitutes 28

4.2.5 Intensity of Rivalry 28

4.3 Investment Opportunities Analysis 29

4.4 Pricing Analysis 29

5 Market, by Type

5.1 Introduction 30

5.2 Prescribed Genetic Testing 32

5.3 Direct to Consumer Genetic Testing 33

6 Market, by Method

6.1 Introduction 34

6.2 Molecular Genetic Tests/ DNA Tests 36

6.3 Chromosomal Genetic Tests 37

6.4 Biochemical Genetic Tests 38

7 Market, by Application

7.1 Introduction 39

7.2 Reproductive Health 41

7.2.1 Newborn Screening 42

7.2.2 Prenatal Screening 43

7.2.3 Carrier Screening 43

7.3 Cancer Screening 44

7.3.1 Hereditary Cancer 45

7.3.2 Breast Cancer 46

7.3.3 Ovarian Cancer 46

7.3.4 Colon Cancer 47

7.4 Ancestry 47

7.5 Predictive and Pre-Symptomatic Testing 48

7.6 Others 48

8 Global Market, by Region

8.1 Introduction 49

8.2 Americas 51

Market, by Type

Market, by Method

Market, by Application

8.2.1 North America 54

Market, by Type

Market, by Method

Market, by Application

8.2.1.1 US 58

Market, by Type

Market, by Method

Market, by Application

8.2.1.2 Canada 60

Market, by Type

Market, by Method

Market, by Application

8.2.2 South America 63

Market, by Type

Market, by Method

Market, by Application

8.3 Europe 66

Market, by Type

Market, by Method

Market, by Application

8.3.1 Western Europe 69

Market, by Type

Market, by Method

Market, by Application

8.3.1.1 Germany 73

Market, by Type

Market, by Method

Market, by Application

8.3.1.2 France 75

Market, by Type

Market, by Method

Market, by Application

8.3.1.3 UK 78

Market, by Type

Market, by Method

Market, by Application

8.3.1.4 Italy 80

Market, by Type

Market, by Method

Market, by Application

8.3.1.5 Spain 83

Market, by Type

Market, by Method

Market, by Application

8.3.1.6 Rest of Western Europe 85

Market, by Type

Market, by Method

Market, by Application

8.3.2 Eastern Europe 88

Market, by Type

Market, by Method

Market, by Application

8.4 Asia-Pacific 91

Market, by Type

Market, by Method

Market, by Application

8.4.1 Japan 94

Market, by Type

Market, by Method

Market, by Application

8.4.2 China 97

Market, by Type

Market, by Method

Market, by Application

8.4.3 India 99

Market, by Type

Market, by Method

Market, by Application

8.4.4 Australia 102

Market, by Type

Market, by Method

Market, by Application

8.4.5 South Korea 104

Market, by Type

Market, by Method

Market, by Application

8.4.6 Rest of Asia-Pacific 107

Market, by Type

Market, by Method

Market, by Application

8.5 Middle East and Africa 110

Market, by Type

Market, by Method

Market, by Application

8.5.1 Middle East 113

Market, by Type

Market, by Method

Market, by Application

8.5.2 Africa 116

Market, by Type

Market, by Method

Market, by Application

9 Company Landscape

9.1 Company Share Analysis 119

10 Company Profiles

10.1 Abbott Laboratories 120

10.1.1 Company Overview 120

10.1.2 Financial Overview 120

10.1.3 Products/Services Offered 121

10.1.4 Key Developments 121

10.1.5 SWOT Analysis 121

10.1.6 Key Strategies 122


10.2 Bio- Rad Laboratories, Inc. 123

10.2.1 Company Overview 123

10.2.2 Financial Overview 123

10.2.3 Products/Services Offered 124

10.2.4 Key Developments 124

10.2.5 SWOT Analysis 124

10.2.6 Key Strategies 125

10.3 Illumina Inc. 126

10.3.1 Company Overview 126

10.3.2 Financial Overview 126

10.3.3 Products/Services Offered 127

10.3.4 Key Developments 127

10.3.5 SWOT Analysis 128

10.3.6 Key Strategies 128

10.4 Myriad Genetics, Inc. 129

10.4.1 Company Overview 129

10.4.2 Financial Overview 129

10.4.3 Products/Services Offered 130

10.4.4 Key Developments 130

10.4.5 SWOT Analysis 131

10.4.6 Key Strategies 131

10.5 PerkinElmer Inc. 132

10.5.1 Company Overview 132

10.5.2 Financial Overview 132

10.5.3 Products/Services Offered 133

10.5.4 Key Developments 133

10.5.5 SWOT Analysis 133

10.5.6 Key Strategies 133

10.6 QIAGEN 134

10.6.1 Company Overview 134

10.6.2 Financial Overview 134

10.6.3 Products/Services Offered 135

10.6.4 Key Developments 135

10.6.5 SWOT Analysis 135

10.6.6 Key Strategies 136

10.7 Quest Diagnostics Incorporated 137

10.7.1 Company Overview 137

10.7.2 Financial Overview 137

10.7.3 Products/Services Offered 138

10.7.4 Key Developments 138

10.7.5 SWOT Analysis 138

10.7.6 Key Strategies 138

10.8 Eurofins Scientific 139

10.8.1 Company Overview 139

10.8.2 Financial Overview 139

10.8.3 Products/Services Offered 140

10.8.4 Key Developments 140

10.8.5 SWOT Analysis 140

10.8.6 Key Strategies 141

10.9 F. Hoffmann-La Roche Ltd 142

10.9.1 Company Overview 142

10.9.2 Financial Overview 142

10.9.3 Products/Services Offered 143

10.9.4 Key Developments 143

10.9.5 SWOT Analysis 143

10.9.6 Key Strategies 143

10.10 Blueprint Genetics 144

10.10.1 Company Overview 144

10.10.2 Financial Overview 144

10.10.3 Products/Services Offered 144

10.10.4 Key Developments 144

10.10.5 SWOT Analysis 144

10.10.6 Key Strategies 145

10.11 Thermo Fisher Scientific Inc. 146

10.11.1 Company Overview 146

10.11.2 Financial Overview 146

10.11.3 Products/Services Offered 147

10.11.4 Key Developments 147

10.11.5 SWOT Analysis 147

10.11.6 Key Strategies 148

10.12 BGI Genomics 149

10.12.1 Company Overview 149

10.12.2 Financial Overview 149

10.12.3 Products/Services Offered 149

10.12.4 Key Developments 149

10.12.5 SWOT Analysis 150

10.12.6 Key Strategies 150

11 List of Tables

TABLE 1 LIST OF ASSUMPTIONS 16

TABLE 2 GLOBAL GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 31

TABLE 3 GLOBAL GENETIC TESTING MARKET FOR PRESCRIBED GENETIC TESTING, BY REGION, 2020–2027 (USD MILLION) 32

TABLE 4 GLOBAL GENETIC TESTING MARKET FOR DIRECT TO CONSUMER GENETIC TESTING, BY REGION, 2020–2027 (USD MILLION) 33

TABLE 5 GLOBAL GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 35

TABLE 6 GLOBAL GENETIC TESTING MARKET FOR MOLECULAR GENETIC TESTS/ DNA TESTS, BY REGION, 2020–2027 (USD MILLION) 36

TABLE 7 GLOBAL GENETIC TESTING MARKET FOR CHROMOSOMAL GENETIC TESTS, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 8 GLOBAL GENETIC TESTING MARKET FOR BIOCHEMICAL GENETIC TESTS, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 9 GLOBAL GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 40

TABLE 10 GLOBAL GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 41

TABLE 11 GLOBAL GENETIC TESTING MARKET FOR REPRODUCTIVE HEALTH, BY REGION, 2020–2027 (USD MILLION) 42

TABLE 12 GLOBAL GENETIC TESTING MARKET FOR NEWBORN SCREENING, BY REGION, 2020–2027 (USD MILLION) 42

TABLE 13 GLOBAL GENETIC TESTING MARKET FOR PRENATAL SCREENING, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 14 GLOBAL GENETIC TESTING MARKET FOR CARRIER SCREENING, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 15 GLOBAL GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 44

TABLE 16 GLOBAL GENETIC TESTING MARKET FOR CANCER SCREENING, BY REGION, 2020–2027 (USD MILLION) 45

TABLE 17 GLOBAL GENETIC TESTING MARKET FOR HEREDITARY CANCER, BY REGION, 2020–2027 (USD MILLION) 45

TABLE 18 GLOBAL GENETIC TESTING MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 19 GLOBAL GENETIC TESTING MARKET FOR OVARIAN CANCER, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 20 GLOBAL GENETIC TESTING MARKET FOR COLON CANCER, BY REGION, 2020–2027 (USD MILLION) 47

TABLE 21 GLOBAL GENETIC TESTING MARKET FOR ANCESTRY, BY REGION, 2020–2027 (USD MILLION) 47

TABLE 22 GLOBAL GENETIC TESTING MARKET FOR PREDICTIVE AND PRE-SYMPTOMATIC TESTING, BY REGION,

2020–2027 (USD MILLION) 48

TABLE 23 GLOBAL GENETIC TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 50

TABLE 24 AMERICAS: GENETIC TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 51

TABLE 25 AMERICAS: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 26 AMERICAS: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 52

TABLE 27 AMERICAS: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 53

TABLE 28 AMERICAS: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 29 AMERICAS: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 30 NORTH AMERICA: GENETIC TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 55

TABLE 31 NORTH AMERICA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

TABLE 32 NORTH AMERICA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 56

TABLE 33 NORTH AMERICA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 56

TABLE 34 NORTH AMERICA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 35 NORTH AMERICA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 36 US: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 37 US: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 58

TABLE 38 US: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 59

TABLE 39 US: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 40 US: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 41 CANADA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 42 CANADA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 61

TABLE 43 CANADA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 61

TABLE 44 CANADA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 45 CANADA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 46 SOUTH AMERICA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 47 SOUTH AMERICA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 63

TABLE 48 SOUTH AMERICA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 64

TABLE 49 SOUTH AMERICA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 50 SOUTH AMERICA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 51 EUROPE: GENETIC TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 66

TABLE 52 EUROPE: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 53 EUROPE: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 67

TABLE 54 EUROPE: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 68

TABLE 55 EUROPE: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 56 EUROPE: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 57 WESTERN EUROPE: GENETIC TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 70

TABLE 58 WESTERN EUROPE: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 59 WESTERN EUROPE: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 71

TABLE 60 WESTERN EUROPE: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 71

TABLE 61 WESTERN EUROPE: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 62 WESTERN EUROPE: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 63 GERMANY: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 64 GERMANY: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 73

TABLE 65 GERMANY: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 74

TABLE 66 GERMANY: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 67 GERMANY: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 68 FRANCE: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 69 FRANCE: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 76

TABLE 70 FRANCE: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 76

TABLE 71 FRANCE: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 72 FRANCE: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 73 UK: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 74 UK: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 78

TABLE 75 UK: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 79

TABLE 76 UK: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 77 UK: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 78 ITALY: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 79 ITALY: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 81

TABLE 80 ITALY: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 81

TABLE 81 ITALY: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 82 ITALY: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 83 SPAIN: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 83

TABLE 84 SPAIN: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 83

TABLE 85 SPAIN: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 84

TABLE 86 SPAIN: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 87 SPAIN: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 88 REST OF WESTERN EUROPE: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 89 REST OF WESTERN EUROPE: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 86

TABLE 90 REST OF WESTERN EUROPE: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 86

TABLE 91 REST OF WESTERN EUROPE: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 87

TABLE 92 REST OF WESTERN EUROPE: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 87

TABLE 93 EASTERN EUROPE: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 94 EASTERN EUROPE: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 88

TABLE 95 EASTERN EUROPE: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 89

TABLE 96 EASTERN EUROPE: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 97 EASTERN EUROPE: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 90

TABLE 98 ASIA-PACIFIC: GENETIC TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91

TABLE 99 ASIA-PACIFIC: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 92

TABLE 100 ASIA-PACIFIC: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 92

TABLE 101 ASIA-PACIFIC: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 93

TABLE 102 ASIA-PACIFIC: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 93

TABLE 103 ASIA-PACIFIC: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 94

TABLE 104 JAPAN: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 94

TABLE 105 JAPAN: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 95

TABLE 106 JAPAN: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 95

TABLE 107 JAPAN: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 96

TABLE 108 JAPAN: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 96

TABLE 109 CHINA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 97

TABLE 110 CHINA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 97

TABLE 111 CHINA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98

TABLE 112 CHINA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 98

TABLE 113 CHINA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 99

TABLE 114 INDIA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 99

TABLE 115 INDIA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 100

TABLE 116 INDIA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 100

TABLE 117 INDIA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 118 INDIA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 119 AUSTRALIA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 102

TABLE 120 AUSTRALIA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 102

TABLE 121 AUSTRALIA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 103

TABLE 122 AUSTRALIA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 103

TABLE 123 AUSTRALIA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 124 SOUTH KOREA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 125 SOUTH KOREA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 105

TABLE 126 SOUTH KOREA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 105

TABLE 127 SOUTH KOREA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 106

TABLE 128 SOUTH KOREA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 106

TABLE 129 REST OF ASIA-PACIFIC: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 107

TABLE 130 REST OF ASIA-PACIFIC: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 107

TABLE 131 REST OF ASIA-PACIFIC: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 108

TABLE 132 REST OF ASIA-PACIFIC: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 108

TABLE 133 REST OF ASIA-PACIFIC: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 109

TABLE 134 MIDDLE EAST & AFRICA: GENETIC TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 110

TABLE 135 MIDDLE EAST & AFRICA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 111

TABLE 136 MIDDLE EAST & AFRICA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 111

TABLE 137 MIDDLE EAST & AFRICA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 112

TABLE 138 MIDDLE EAST & AFRICA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 112

TABLE 139 MIDDLE EAST & AFRICA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 113

TABLE 140 MIDDLE EAST: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 113

TABLE 141 MIDDLE EAST: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 114

TABLE 142 MIDDLE EAST: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114

TABLE 143 MIDDLE EAST: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 115

TABLE 144 MIDDLE EAST: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 115

TABLE 145 AFRICA: GENETIC TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION) 116

TABLE 146 AFRICA: GENETIC TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 116

TABLE 147 AFRICA: GENETIC TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 117

TABLE 148 AFRICA: GENETIC TESTING MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020–2027 (USD MILLION) 117

TABLE 149 AFRICA: GENETIC TESTING MARKET, FOR CANCER SCREENING, BY TYPE, 2020–2027 (USD MILLION) 118

12 List of Figures

FIGURE 1 GLOBAL GENETIC TESTING MARKET: MARKET STRUCTURE 16

FIGURE 2 RESEARCH PROCESS OF MRFR 17

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACHES 20

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL MARKET 21

FIGURE 5 VALUE CHAIN: GLOBAL MARKET 25

FIGURE 6 PORTER’S FIVE FORCES ANALYSIS: GLOBAL MARKET 27

FIGURE 7 GLOBAL MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 30

FIGURE 8 GLOBAL MARKET, BY METHOD, 2020 & 2027 (USD MILLION) 34

FIGURE 9 GLOBAL MARKET, BY APPLICATION, 2020 & 2027 (USD MILLION) 39

FIGURE 10 GLOBAL MARKET, FOR REPRODUCTIVE HEALTH, BY TYPE, 2020 & 2027 (USD MILLION) 41

FIGURE 11 GLOBAL MARKET, FOR CANCER SCREENING, BY TYPE, 2020 & 2027 (USD MILLION) 44

FIGURE 12 GLOBAL, MARKET BY REGION, 2020 & 2027 (USD MILLION) 49

FIGURE 13 AMERICAS: MARKET SHARE, BY REGION, 2020 (%) 51

FIGURE 14 NORTH AMERICA: GENETIC TESTING MARKET SHARE, BY COUNTRY, 2020 (%) 54

FIGURE 15 EUROPE: MARKET SHARE, BY REGION, 2020 (%) 66

FIGURE 16 WESTERN EUROPE: MARKET SHARE, BY COUNTRY, 2020 (%) 69

FIGURE 17 ASIA-PACIFIC: MARKET SHARE, BY COUNTRY, 2020 (%) 91

FIGURE 18 MIDDLE EAST & AFRICA: MARKET SHARE, BY REGION, 2020 (%) 110

FIGURE 19 GLOBAL MARKET, COMPANY SHARE ANALYSIS, 2020 (%) 119

遺伝子検査市場

遺伝子検査市場は10.30%のCAGRで登録されると予測されており、2027年までに3010億米ドルの市場価値を獲得すると予想されています

セグメンテーション

タイプ別 Prescribed Genetic Testing Direct To Consumer Genetic Testing
By Method Molecular Genetic Tests/ Dna Tests Chromosomal Genetic Tests Biochemical Genetic Tests
アプリケーション別 Reproductive Health Cancer Screening Ancestry Predictive And Pre Symptomatic Testing Others

キープレーヤー

  • PerkinElmer Inc. (US)
  • Myriad Genetics Inc. (US)
  • Abbott Laboratories (US)
  • Illumina Inc. (US)
  • Bio-Rad Laboratories Inc. (the US)
  • QIAGEN (Germany)
  • Eurofins Scientific (US)
  • Quest Diagnostics Incorporated (US)
  • Hoffmann-La Roche Ltd (Switzerland)
  • Thermo Fisher Scientific Inc. (US)

運転手

  • Increasing prevalence of genetic disorders
  • Increasing need to find a cure to cancer
Speak to Analyst Request a Free Sample

遺伝子検査市場の概要


Market Research Future(MRFR)が実施した分析によると、遺伝子検査市場は10.30%のCAGRで繁栄すると予測されており、2027年までに3010億米ドルの市場価値を獲得すると予想されています。


遺伝子検査は、出生前のスクリーニング、診断、および予測ツールとして使用されます。遺伝子検査市場は、有用な検査キットを製造するための現場での開発が進行中であるため、推進すると予測されています。全体として、遺伝子検査市場は、そのニーズの高まり、買収の増加、主要企業間のパートナーシップにより、大幅な拡大を経験する可能性があります。


COVID-19の発生は、遺伝子検査市場に深刻な影響を与えました。社会的距離を追跡するための世界的な封鎖は、遺伝子検査市場にさまざまな課題をもたらしました。COVID-19の結果、テストラボとクリニックが閉鎖され、市場に悪影響を与える可能性のある対面式の遺伝カウンセリングが制限されました。


マーケットダイナミクス


腫瘍学における遺伝子検査の需要の高まりと臨床ケアへの遺伝子検査の採用の増加は、予測期間中の遺伝子検査市場を推進すると予測されています。個別化医療の必要性の高まりは、遺伝子検査の市場規模を拡大する可能性のあるもう1つの顕著な原因です。


しかし、遺伝子検査に基づく診断の標準化に関する懸念と、製品承認のために実施される厳格な規則は、評価中の遺伝子検査市場の成長を妨げると予想されます。ピリオド。


ドライバー


遺伝性疾患の有病率の上昇


遺伝子検査の利点に対する意識の高まりと遺伝性疾患の有病率の増加は、遺伝子検査市場の成長の主要な推進力です。がんの治療法を見つける必要性が高まっているため、世界のがん検査市場を拡大できる効果的な検査の需要が生まれると予想されます。さらに、バイオテクノロジーセクターの急速な拡大は、評価期間中に遺伝子検査市場を大幅に推進すると予想されます。


機会


テスト手順におけるAIの統合


遺伝子検査におけるAIやその他のスマートテクノロジーの統合は、予測期間中にさまざまな市場拡大の機会を提供すると予想されます。その上、製品設計の革新と強力な流通パートナーシップは、貿易を成長させる有利な機会を提供できる他の要因です。


拘束


市場の成長を妨げる専門知識の欠如


市場を成長させるさまざまな有利な機会が存在するにもかかわらず、訓練を受けた技術者の不足は、新興国の遺伝子検査市場を妨げる可能性のある重要な要因です。


チャレンジ


診断されたすべての疾患に対する医療ソリューションの欠如


遺伝子検査市場における最大の課題は、診断されたすべての疾患に対する解決策がないことです。しかし、発見後の予後に関する資金提供を受けた研究は、上記の課題に対抗することができます。


累積成長分析


遺伝子検査市場は、遺伝性疾患の意識の高まりにより、予測期間中に急速に拡大すると予想されます。業界は、今後さまざまな拡大の機会を目の当たりにすると予想されています。


市場細分化


タイプ別


最大の市場シェアを保持するために処方された遺伝子検査セグメント


タイプに基づいて、世界の遺伝子検査市場は、消費者向け遺伝子検査と処方された遺伝子検査に直接分割されています。すべての遺伝子検査市場セグメントの中で、処方された遺伝子検査市場は、2024年までに2億6,5391万米ドルの市場価値を獲得しながら、最高のCAGRで拡大すると予想されています。


方法別


最大の市場シェアを維持するための分子遺伝学的検査/DNA検査


この方法に基づいて、世界の遺伝子検査市場は、染色体遺伝子検査、分子遺伝子検査/ DNA検査、および生化学的、遺伝子検査に分割されています。とりわけ、分子遺伝/ DNA検査は、予測期間中に11.78%のCAGRで繁栄しながら、世界市場をリードすると予想されています。


アプリケーション別


リプロダクティブヘルス部門が最大の市場シェアを獲得


アプリケーションに基づいて、世界市場はがん検診、リプロダクティブヘルス、祖先、予測および症状前検査などに分割されています。とりわけ、リプロダクティブヘルスセグメントが市場を支配すると予想されます。


地域分析


遺伝性疾患の発生率の増加によりアメリカ大陸が市場を支配する


アメリカ大陸は、遺伝性疾患の発生率の増加と個別化遺伝子検査の需要の増加により、遺伝子検査の市場を支配すると予想されています。政府の支援の高まりと先進医療セクターの存在は、予測期間中に地域市場を後押しすると予想されます。


APACは、発展途上国における患者プールの拡大と未開拓の市場機会により、最も急速に成長する市場になると予想されています。さらに、増加する高齢者人口の需要を満たすためのヘルスケアインフラストラクチャを開発するイニシアチブの成長は、レビュー期間中に地域市場をさらに推進する可能性があります。


遺伝子検査のヨーロッパ市場は、予測期間中に2番目に大きいと予測されています。ヨーロッパにおける分子医薬品の最近の発展と進歩は、この遺伝子検査市場の成長にとって重要な要素です。遺伝性疾患および遺伝性疾患の有病率の増加により、さまざまな遺伝子検査の開発の範囲が拡大しています。


MEAは、人口の高齢化、癌などの慢性疾患の数の増加、および遺伝子検査の革新により増加すると予想されます。


競争環境


主要企業間の競争を激化させる遺伝子検査プラットフォームの製品革新


遺伝子検査の市場は非常に競争が激しく、いくつかの確立されたプレーヤーで構成されています。オンになっている



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: USD 30.10 Billion
  CAGR   10.30% (2020-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Method, Application, Cancer Screening,
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   PerkinElmer Inc. (US), Myriad Genetics Inc. (US), Abbott Laboratories (US), Illumina Inc. (US), Bio-Rad Laboratories Inc. (the US), QIAGEN (Germany), Eurofins Scientific (US), Quest Diagnostics Incorporated (US), Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Blueprint Genetics (Finland), BGI Genomics (China)
  Key Market Opportunities   Integration of AI in Testing Procedures
  Key Market Drivers   Rising Prevalence of Genetic Disorders


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Genetic testing market volume by 2027 would be USD 30.10 Billion

The genetic testing market would attain a CAGR of 10.30% By 2027

High cost and inaccuracy could prevent the genetic testing market growth.

The Americas would have a maximum genetic testing market share.

Japan had a 27.7% share of the Asia Pacific genetic testing market in 2018.